NCT00115804View on ClinicalTrials.gov

Safety and Efficacy of Fluoxetine in Juvenile Fibromyalgia

PHASE3CompletedINTERVENTIONAL
Enrollment

6

Participants

Timeline

Start Date

June 30, 2005

Primary Completion Date

February 28, 2011

Study Completion Date

February 28, 2011

Conditions
Juvenile Primary Fibromyalgia Syndrome (JPFS)Fibromyalgia
Interventions
DRUG

Fluoxetine

Fluoxetine po 10-60 mg/day for 12 weeks. Fluoxetine was started at 10 mg once daily. The dose was flexibly dosed based on pain efficacy and tolerability to a final dose between 10 and 60 mg once daily

Trial Locations (1)

45219

Women's Health Research Program, Cincinnati

All Listed Sponsors
lead

University of Cincinnati

OTHER

NCT00115804 - Safety and Efficacy of Fluoxetine in Juvenile Fibromyalgia | Biotech Hunter | Biotech Hunter